Elutia to Present at Sidoti’s Small-Cap Virtual Investor Conference March 18-19

Rhea-AI Summary

Elutia (Nasdaq: ELUT) will present at the Sidoti Small-Cap Virtual Investor Conference on March 18–19, 2026. Management will discuss the company’s drug-eluting biomatrix technology aimed at reducing post-surgical infection in implant-based breast reconstruction.

The presentation starts at 2:30 p.m. ET on March 19, 2026; registration and one-on-one investor meetings are available via Sidoti’s event site.

News Market Reaction – ELUT

+1.87%

1 alert

+1.87% News Effect

On the day this news was published, ELUT gained 1.87%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: March 18–19, 2026 Presentation time: 2:30 p.m. Eastern Time

2 metrics

Conference dates March 18–19, 2026 Sidoti Small-Cap Virtual Investor Conference schedule

Presentation time 2:30 p.m. Eastern Time Elutia management presentation on March 19, 2026

Market Reality Check

Price: $1.08 Vol: Volume 394,364 vs 20-day ...

high vol

$1.08 Last Close

Volume Volume 394,364 vs 20-day average 211,279 (relative volume 1.87x) ahead of the conference news. high

Technical Shares at $1.07 are trading below the 200-day MA of $1.28 and 69.08% under the 52-week high of $3.46.

Peers on Argus

ELUT was at $1.07, down 0.93% pre-news, while momentum peers ICCM, MDAI, and APY...

3 Up

ELUT was at $1.07, down 0.93% pre-news, while momentum peers ICCM, MDAI, and APYX each showed small upside moves. Key listed peers had mixed moves (e.g., CTSO -9.71%, TELA -5.67%, SRTS +1.54%), indicating stock-specific factors rather than a unified sector trend.

Historical Context

5 past events · Latest: Mar 13 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 13	Inducement equity awards	Negative	-6.1%	Granted 460,000 stock options at $1.09 to new employees.
Mar 11	Earnings and strategy	Positive	+5.5%	Reported 2025 results and NXT-41 regulatory progress with stronger balance sheet.
Mar 04	Nasdaq compliance regained	Positive	-2.5%	Regained compliance with Nasdaq bid price and market value requirements.
Mar 02	CCO appointment	Positive	-0.9%	Named CCO to lead NXT-41x commercial launch in breast reconstruction market.
Feb 25	Earnings date set	Neutral	+5.5%	Scheduled Q4 2025 results call and webcast for March 11, 2026.

Pattern Detected

Recent news often produced mixed reactions: positive strategic and regulatory updates sometimes saw negative follow-through, while financial updates and event notices occasionally coincided with gains.

Recent Company History

Over recent weeks, ELUT has reported several milestones. On Mar 11, 2026, it posted Q4 and 2025 results, highlighting an $88.0M asset sale and balance-sheet improvement, with shares rising 5.5%. Compliance with Nasdaq listing standards on Mar 4 and the appointment of a CCO to lead the NXT-41x launch drew modest or negative reactions. Inducement equity awards on Mar 13 coincided with a larger one-day decline. Today’s conference appearance fits into this ongoing investor-relations cadence.

Market Pulse Summary

This announcement centers on Elutia’s participation in an investor conference, emphasizing its drug-...

Analysis

This announcement centers on Elutia’s participation in an investor conference, emphasizing its drug-eluting biomatrix platform for implant-based breast reconstruction and post-surgical infection risk. It follows recent milestones such as regulatory progress for NXT-41 and balance-sheet reshaping via asset sales. Investors may focus on how management frames the Women’s Health opportunity, commercialization plans for NXT-41x, and updates relative to prior earnings and 10-K disclosures.

Key Terms

drug-eluting biomatrix, post-surgical infection, implant-based breast reconstruction, mastectomy, +1 more

5 terms

drug-eluting biomatrix medical

"a pioneer in drug-eluting biomatrix technologies, today announced that Dr."

A drug-eluting biomatrix is a medical implant or coating made of biocompatible material that slowly releases a drug at a controlled rate where it is placed in the body, like a sponge that steadily releases medicine into surrounding tissue. For investors, it matters because such technology can improve treatment effectiveness, reduce side effects and repeat procedures, and therefore influence product value, regulatory risk and long-term revenue potential for medical-device and pharmaceutical companies.

post-surgical infection medical

"will discuss how Elutia is working to address post-surgical infection in implant-based"

An infection that develops at the site of a surgical procedure or inside the body after an operation, caused by bacteria, fungi, or other microbes entering tissues or implants. For investors, post-surgical infections matter because they can increase a healthcare provider’s or device maker’s costs, trigger recalls or legal claims, delay patient recovery and sales, and draw regulatory scrutiny—similar to a construction defect that raises repair bills, damages reputation, and reduces future demand.

implant-based breast reconstruction medical

"infection in implant-based breast reconstruction following mastectomy—one of the most"

A surgical approach that rebuilds a breast using a manufactured implant—usually saline or silicone—placed under the chest muscle or skin after breast tissue is removed or damaged. For investors, it signals demand for specific medical devices, surgical consumables and related services, and brings exposure to product safety rules, reimbursement policies and litigation risk; think of it like replacing a removed car part with an aftermarket component.

mastectomy medical

"breast reconstruction following mastectomy—one of the most significant challenges"

Mastectomy is a surgical procedure that removes all or part of breast tissue, usually to treat or prevent breast cancer. Investors follow mastectomy trends because changes in how often or which type of mastectomy is performed can affect demand for related drugs, medical devices, reconstructive services and insurance payouts—think of it like a market signal that shifts which products and services hospitals and patients will need.

revision surgeries medical

"remains a leading cause of complications and revision surgeries for patients"

Revision surgeries are follow-up operations performed to correct, replace, or improve the outcome of a previous surgical procedure—like fixing or upgrading a device that didn’t last or caused problems. For investors, they matter because the frequency of revisions signals product durability, ongoing revenue for device makers and hospitals, potential liability or warranty costs, and future demand for replacement procedures, much like repair work indicates the quality and service needs of a manufactured product.

AI-generated analysis. Not financial advice.

GAITHERSBURG, Md., March 17, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Matt Ferguson, PhD, Chief Financial Officer, will present and host one-on-one meetings with investors at the Sidoti Small-Cap Virtual Investor Conference, taking place March 18–19, 2026.

During the presentation, management will discuss how Elutia is working to address post-surgical infection in implant-based breast reconstruction following mastectomy—one of the most significant challenges facing patients and surgeons—through its drug-eluting biomatrix technology designed to support safer, more reliable reconstructive outcomes.

The Company will highlight its focus on improving outcomes in implant-based breast reconstruction, where infection remains a leading cause of complications and revision surgeries for patients undergoing reconstruction after breast cancer treatment.

The presentation will begin at 2:30 p.m. Eastern Time on March 19, 2026, and can be accessed live here: Webinar Registration - Zoom.

Elutia will also host virtual one-on-one meetings with investors on March 18–19, 2026.

To register for the presentation or schedule a one-on-one meeting, visit www.sidoti.com/events. Registration is free and does not require Sidoti client status.

About Sidoti Events, LLC (“Events”) and Sidoti & Company, LLC (“Sidoti”)
In 2023, Sidoti & Company, LLC , Sidoti & Company, LLC formed an affiliate company, Sidoti Events, LLC in order to focus exclusively on its rapidly growing conference business and to more directly serve the needs of presenters and attendees.  The relationship allows Events to draw on the over 25 years of experience Sidoti has as a premier provider of independent securities research focused specifically on small and microcap companies and the institutions that invest in their securities, with most of its coverage in the $200 million-$5 billion market cap range. Sidoti’s coverage universe comprises approximately 150 equities, of which almost 70 percent participate in the firm's rapidly growing Company Sponsored Research ("CSR") and Sidoti Lighthouse Equity Research (“Lighthouse”) programs.  Events is a leading provider of corporate access through the many investor conferences it hosts each year. By virtue of its direct ties to Sidoti, Events benefits from Sidoti’s small- and microcap-focused nationwide sales force, which has connections with over 2,500 institutional relationships in North America.  This enables Events to provide multiple forums for meaningful interaction for small and microcap issuers and investors specifically interested in companies in the sector.

About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors:
Elutia Investor Relations
ir@elutia.com

FAQ

When will Elutia (ELUT) present at the Sidoti Small-Cap Virtual Investor Conference?

Elutia (NASDAQ: ELUT) will present on March 19, 2026 at 2:30 p.m. Eastern Time. According to the company, CEO Randy Mills and CFO Matt Ferguson will deliver the presentation and host virtual one-on-one investor meetings across March 18–19, 2026.

How can investors access Elutia's (ELUT) Sidoti presentation on March 19, 2026?

Investors can access the presentation via a live Zoom webinar registration link. According to the company, registration is free, open to the public, and available through Sidoti’s events page at www.sidoti.com/events.

Who from Elutia (ELUT) will present and meet investors at the March 18–19, 2026 Sidoti conference?

Elutia’s CEO Randy Mills and CFO Matt Ferguson, PhD, will present and host meetings. According to the company, both executives will discuss the drug-eluting biomatrix technology and hold virtual one-on-one investor sessions.

What topics will Elutia (ELUT) cover during its March 19, 2026 Sidoti presentation?

Elutia will discuss its drug-eluting biomatrix approach to reduce post-surgical infection in implant-based breast reconstruction. According to the company, management will highlight efforts to improve reconstructive outcomes and lower infection-related complications and revisions.

Is registration required or paid to attend Elutia’s (ELUT) Sidoti investor presentation on March 19, 2026?

Registration is required but free to attend the presentation and one-on-one meetings. According to the company, Sidoti client status is not required and sign-up is available on Sidoti’s events registration page.